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Summary 
Genetic studies have revealed an essential role for cytosine DNA methylation in 
mammalian development. However, its spatiotemporal distribution in the developing 
embryo remains obscure. Here, we profiled the methylome landscapes of 12 mouse 
tissues/organs at 8 developmental stages spanning from early embryogenesis to birth. In-
depth analysis of these spatiotemporal epigenome maps systematically delineated ~2 
million methylation variant regions and uncovered widespread methylation dynamics at 
nearly one-half million tissue-specific enhancers, whose human counterparts were 
enriched for variants involved in genetic diseases. Strikingly, these predicted regulatory 
elements predominantly lose CG methylation during fetal development, whereas the 
trend is reversed after birth. Accumulation of non-CG methylation within gene bodies of 
key developmental transcription factors coincided with their transcriptional repression 
during later stages of fetal development. These spatiotemporal epigenomic maps provide 
a valuable resource for studying gene regulation during mammalian tissue/organ 
progression and for pinpointing regulatory elements involved in human developmental 
diseases. 
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Introduction 
Mammalian embryonic development involves spatiotemporal transcriptional 
regulation, which is mediated by sophisticated orchestration of epigenetic modifications 
and transcription factor (TF) binding of regulatory DNA elements, primarily enhancers. 
The accessibility of TFs to regulatory DNA is closely related to the covalent modification 
of histones and DNA1–6. 
Cytosine DNA methylation (mC) is an epigenetic modification that plays a 
critical role in gene regulation7. In the mammalian genome, mC occurs predominantly on 
cytosine followed by guanine (mCG), which is dynamic at regulatory elements in 
different tissues and cell types8–12. In fact, mCG is able to directly affect the DNA 
binding affinity of a variety of transcription factors1,2,6,13–15 and targeted removal/addition 
of mCG in promoters is concomitant with increases/decreases in gene transcription16. 
Non-CG methylation (mCH; H = A, C or T) is also present at an appreciable level in 
embryonic stem cells, oocytes as well as brain, heart, skeletal muscle and a variety of 
adult tissues8–10,17–20. Although its precise function(s) are unknown, mCH abundance 
directly affects DNA binding of MeCP2, the methyl-binding protein responsible for Rett 
Syndrome20–23. 
mC is actively regulated during mammalian development24,25. However, in 
contrast to pre-implantation embryogenesis25–27, data are lacking for the later stages of 
fetal development, during which anatomical features of the major organ systems are more 
evident and human birth defects are manifested28. To fill this knowledge gap, we used the 
experimentally tractable mouse embryo as a model system to profile DNA methylation 
variation. Deep whole-genome bisulfite sequencing8 was performed to comprehensively 
profile cytosine DNA methylation in 12 tissue types (in replicate) for 8 development 
stages starting from embryonic day 10.5 (E10.5) to birth (postnatal day 0, P0; Fig. 1A). 
The temporal mouse fetal tissue/organ epigenomes (Supplemental Table 1) described 
here should inform our understanding of regulatory events occurring during normal 
human fetal progression as well as developmental disorders. These comprehensive 
datasets are publically accessible at 
https://www.encodeproject.org/search/?searchTerm=ecker&type=Experiment&award.rfa
=ENCODE3 and http://neomorph.salk.edu/ENCODE_mouse_fetal_development/. 
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Results 
CG methylation dynamics 
To assess the mC landscape in the developing mouse embryo, 144 high-quality 
tissue methylomes were produced that cover most of the major organ systems and tissue 
types derived from the three primordial germ layers. To obtain an overview of the 
spatiotemporal profile of fetal tissue/organ methylome reconfiguration, we first 
calculated the global mCG level at each developmental stage (Fig. 1a-b; Methods). The 
genomes of all fetal tissues were heavily CG methylated, ranging from 70%-82% with 
the notable exception of liver, which ranged from 60%-74% of CGs and showed large 
domains with partial methylation. Interestingly, such large partially methylated domains 
(PMDs), a genomic feature previously observed in only human cultured cell lines8,29, 
pancreas9, placenta30 and cancer samples31,32 were found exclusively in mouse fetal liver 
(Extended Data Fig. 1). PMD formation and dissolution precisely coincided with fetal 
liver hematopoiesis (see Supplemental Note). Finally, tissues primarily derived from 
ectoderm (forebrain, midbrain, hindbrain and neural tube) showed overall higher mCG 
levels than other tissue types (heart, craniofacial, limb, kidney, lung, stomach, intestine 
and liver). 
Despite similar global mCG levels in fetal tissues, we identified 1,808,810 CG 
differentially methylated regions (CG-DMRs), which are on average 339bp long and 
cover 22.5% (614 Mb) of the mouse genome ((Fig. 1c; Methods). Comprehensive fetal 
tissue CG-DMR annotation captured ~96% (n=272,858) of all previously reported adult 
mouse tissue CG-DMRs12, while finding over 1.5 million new regions (Fig. 1d). 
Surprisingly, only a minority (8.5% or 153,019) of CG-DMRs overlapped with 
promoters, CpG islands (CGIs) or CGI shores (Fig. 1e-f; Extended Data Fig. 2a-c; 
Methods). The vast majority of CG-DMRs (~92.5% or 1,655,791) were distally located 
and showed a high degree of evolutionary conservation, suggesting that they are 
functional (Fig. 1f-g). 
 
Annotating methylation variable regions  
To further classify fetal CG-DMRs, we delineated those genomic regions likely 
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associated with enhancer activity using the REPTILE33 algorithm which allows enhancer 
prediction by integration of the fetal tissue mCG data and histone modification chromatin 
immunoprecipitation sequencing (ChIP-seq) data (Gorkin et al companion paper, this 
issue; Supplemental Table 2). Considering all fetal tissues, except liver, we identified 
487,367 CG-DMRs as fetal enhancer-linked CG-DMRs or feDMRs, 85% (415,227) of 
which are distal to known promoters (Fig. 1f; Methods). feDMRs are evolutionarily 
conserved and show enhancer-like chromatin signatures including the depletion of mCG 
and H3K27me3, and the enrichment of H3K4me1 and H3K27ac8,34–36 (Fig. 1g; Extended 
Data Fig. 2d). Many (106,016) of these enhancers were not previously reported in adult 
mouse tissues37 (Extended Data Fig. 3a). More than 60% of the feDMRs-overlapping 
VISTA enhancer elements38 showed in vivo enhancer activity in E11.5 mouse embryo, 
and this percentage increased for higher scoring feDMRs (Extended Data Fig. 3b). 
Moreover, tissue-specific feDMRs are enriched for TF binding motifs related to specific 
tissue function(s) and are near genes in specific tissue-related pathways (Extended Data 
Fig. 3c; Supplemental Table 3). We found that the human orthologous regions of 
feDMRs significantly overlapped with the disease/trait-associated single nucleotide 
polymorphisms identified from genome-wide association studies and showed tissue-
specificity (Fig. 1h; Supplemental Table 4; Methods).  
We also identified 221,960 CG-DMRs that flank (within 1kb) feDMRs but which 
are not themselves predicted as enhancers (Fig. 1g). These flanking distal feDMRs (fd-
feDMRs) are much less conserved than feDMRs although their mCG level is moderately 
correlated with nearby feDMRs (mean Pearson correlation coefficient = 0.41; see 
Methods), suggesting that a fraction of fd-feDMRs may be the by-product of 
demethylation of the adjacent feDMRs. Alternatively, fd-feDMRs may be bound by 
pioneer TF(s) which allow opening of chromatin of adjacent feDMRs39,40 . This notion is 
supported by the enrichment of binding motifs for several known pioneer TFs39 such as 
FOXA2, GATA3 and PBX1 at fd-DMRs (Supplemental Table 5). Interestingly, binding 
motifs of the insulator protein CTCF and several transcriptional repressors (e.g. CUX141) 
are also enriched at fd-feDMRs, indicating a third possibility that fd-feDMRs correspond 
to insulator and silencer elements (Supplemental Table 5).  
Besides the above CG-DMR classes, another type of distal CG-DMR (n = 
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149,610) are the primed distal feDMRs (pd-feDMRs); these display strong CG 
hypomethylation in at least one tissue sample and are linked to primed fetal enhancers42 
(mCG difference ≥ 0.3; Extended Data Fig. 4a; Methods). In the tissues where they are 
hypomethylated, pd-feDMRs showed chromatin signatures resembling primed 
enhancers42 which are enriched for H3K4me1 while lacking H3K27ac and H3K27me3 
(Extended Data Fig. 4b). Like feDMRs, pd-feDMRs are also evolutionary conserved 
(Fig. 1g). Consistent with their putative role as enhancers, and similar to feDMRs, they 
share significant TF-binding motif signature enrichment in 9 out of the 12 tissue types 
(Extended Data Fig. 4c; Supplemental Table 6). 
The remaining unclassified distal CG-DMRs (868,994) show more subtle CG 
hypomethylation patterns, suggesting that they likely derive from a small fraction of cells 
within these complex tissues/organs (Methods). Since a functional role cannot yet be 
assigned, we named this group “unexplained CG-DMRs” (unxDMR). The genomic 
locations of unxDMRs significantly overlapped with transposable elements (TEs; 58.6%, 
p-value < 0.001; Methods). Inspired by this observation, we divided unxDMRs into two 
subgroups: unxDMRs that overlapped with TE (te-unxDMRs) and ones not overlapping 
(nte-unxDMRs) (Fig. 1F; Extended Data Fig. 4D and E). te-unxDMRs were less 
evolutionarily conserved compared to flanking regions but transposons may be a source 
of novel regulatory elements43. Different from te-unxDMRs, genomic sequences 
underling nte-unxDMRs are as conserved as feDMRs, implying that they may be 
functional. Indeed, 10%-45% of the nte-unxDMRs showed open chromatin in purified 
neurons44 and/or a variety of mouse cell lines and tissues45 (p-value < 1e-3; permutation 
test; Methods). Therefore, nte-unxDMRs are likely regulatory elements active only in 
rare cell types and their weak hypomethylation profiles are due to the tissue 
heterogeneity, highlighting the future necessity of cell type-specific46 or single-cell 
epigenomic studies47.  
 
Distinct pre- and postnatal mCG dynamics 
The dominant methylation pattern that emerged during fetal progression was a 
continuous loss-of-mCG at tissue-specific CG-DMRs, which strongly overlap with 
predicted enhancers (Fig. 2a; Extended Data Fig. 5a-b; Methods). In striking contrast, the 
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gain-of-mCG methylation at CG-DMRs mainly occurred after birth (Fig. 2a; Extended 
Data Fig. 5a). To quantify these changes for each stage interval, we counted loss-of-mCG 
(mCG decreasing by at least 0.1 in one CG-DMR) and gain-of-mCG events (mCG 
increasing by at least 0.1 in one CG-DMR) (Fig. 2b; Methods). During the period from 
E10.5 to P0, 77% to 95% of the mCG changes involved loss-of-mCG, depending on the 
tissue examined. More than 70% of the loss-of-mCG events occurred between E10.5 to 
E13.5 in all tissues except in heart (44%; Fig. 2a; Extended Data Fig. 5c). The mCG level 
of 44-84% tissue-specific CG-DMRs dropped to below 0.5 at E14.5, compared to only 
16-31% at E10.5. Since allele-specific methylation is relatively rare9, the observed 
methylation dynamics suggest that after E14.5, most of the tissue-specific CG-DMRs are 
unmethylated in more than half of the cells in a tissue. 
Compared to the loss of mCG, the vast majority (57%-86%) of gain-of-mCG 
events happened after birth (Extended Data Fig. 5d). As a result, 27%-56% of the tissue-
specific CG-DMRs become highly methylated (mCG level > 0.6) in adult tissues (at least 
4 weeks old), while the number is 0.3%-15% at birth (P0), reflecting the silencing of fetal 
regulatory elements (Extended Data Fig. 6a). The absence of gain-of-mCG events during 
fetal development may be a result of limited de novo CG methylation and/or excessive 
demethylation activity.  
The observed mCG dynamics cannot be explained by the lack of expression of 
cytosines methytransferases Dnmt1 and Dnmt3a nor the co-factor Uhrf148, all of which 
are highly expressed between E10.5 and E13.5 when major the loss-of-mCG events occur 
(Extended Data Fig. 6b). Furthermore, we also did not find increased expression of Tet 
methylcytosine dioxygenases, involved methylation removal49, during the same period. 
Interestingly, Tet3 expression is lower in heart, coinciding with its less dynamic mCG 
during embryogenesis. Absence of gain-of-methylation events until the postnatal period 
may involve translational and/or posttranslational regulation of these enzymes or possibly 
other unknown control mechanisms. Importantly, WGBS does not distinguish between 5-
methylcytosine and 5-hydroxymethylcytosine50. Based on earlier studies10,51, the 
contribution of 5-hydroxymethylcytosine to the total of cytosine modifications can be 
relatively minor. However, future studies that directly measure the full complement of 
cytosine modifications (5-hydroxymethylcytosine, 5-formylcytosine and 5-
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carboxylcytosine) are needed to understand their dynamics during fetal tissue 
development.  
 
Dynamic mCG and chromatin states 
To further pinpoint the timing of CG-DMR remethylation and its relationship 
with enhancer activity, we included methylation data from adult frontal cortex10 as well 
as H3K27ac ChIP-seq data from adult forebrain52 (Supplemental Table 2). Using these 
additional datasets, we further refined the timing of remethylation in the frontal cortex. 
We clustered forebrain-specific CG-DMRs into 8 groups based on the mCG and 
H3K27ac dynamics across both fetal and adult stages (Fig. 2e; Extended Data Fig. 6c; 
Methods). Between the 1st and 2nd postnatal weeks, methylation of forebrain-specific CG-
DMRs increased dramatically and was even further methylated during tissue maturation 
(Extended Data Fig. 6d).  
We then asked how the mCG dynamics at tissue-specific CG-DMRs were 
associated with their enhancer activity (approximated by H3K27ac abundance) during 
development. Interestingly, although the temporal depletion of mCG was not necessarily 
related to high H3K27ac enrichment (e.g. cluster 3, 5 and 6), a high cytosine methylation 
state was indicative of a low H3K27ac state (Fig. 2e-f). Only 2-9% of the highly 
methylated CG-DMRs (mCG level > 0.6) showed high H3K27ac enrichment (>6) and the 
numbers increase to 25-28% for lowly methylated CG-DMRs (mCG level < 0.2; Fig. 2f). 
These observations suggest that the decreasing methylation during development may 
prime dynamic regulation of enhancer activity promoted by increased TF binding and/or 
altered histone modifications. 
 
mCG dynamics and gene module expression 
We next investigated the association between differential mCG and the 
transcription of genes in different pathways, using RNA-seq data from the same 
tissue/organ samples (Wold et al. see companion paper, this issue). By applying an 
unsupervised, weighted correlation network analysis (WGCNA)53 method, we identified 
33 co-expressed gene clusters (co-expression modules, CEMs) and calculated 
“eigengenes” to summarize the expression profile of genes within modules (Fig. 3a-b; 
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Extended Data Fig. 7a-b; Methods). Genes sharing similar expression profiles are more 
likely to be regulated by a common mechanism and/or involved in the same pathway. For 
example, CEM12 contains genes that are highly expressed in early developmental stages 
but are down regulated as tissues mature (Fig. 3c; Extended Data Fig. 7b). Genes in 
CEM12 are significantly related to cell cycle, matching our knowledge that cells become 
post-mitotic in mature tissues. Similarly, genes in CEM3 are related to chromatin 
modification and are lowly expressed in heart, which showed less mCG dynamics 
relative to other tissues (Fig. 3b-c; Extended Data Fig. 7c). Overall, genes in CEMs are 
associated with different pathways and/or biological processes (Extended Data Fig. 7d; 
Supplemental Table 7). 
To understand how mCG profiles and enhancer activity of regulatory elements 
(feDMRs) are associated with the expression of genes in CEMs, we first linked feDMRs 
to the neighboring genes. Next, for each CEM, we correlated its eigengene expression 
with the average mCG and enhancer score (as approximate enhancer activity) of the 
feDMRs linked to the genes in that CEM (Methods). To tease out the effect of tissue type 
and development, we calculated the correlations separately for tissue-specific expression 
and temporal expression (Methods). These analyses revealed that for a given 
developmental stage methylation of feDMRs was negatively correlated with the tissue-
specific eigengene expression, consistent with its known repressive role (Fig. 3d-e). In 
contrast, the enhancer score of feDMRs was positively correlated with tissue-specific 
transcription, implying that enhancers likely drive tissue-specific expression (Fig. 3d-e). 
Such trends hold for the correlations across all modules (Fig. 3e; Methods). Next, for a 
given tissue type, we calculated the correlation across developmental time. The enhancer 
score remains positively correlated with the temporal expression, implying that enhancer 
activity is also the driver of temporal gene expression (Fig. 3f-g). In contrast, because 
mCG generally decreased at feDMRs over development, it only showed marginally better 
anti-correlation than that expected by chance alone (Fig. 2a; Fig. 3f-g).  
 
Large tissue-specific CG-DMRs 
 In neuronal cells and human tissues, some CG-DMRs were found in large 
clusters, forming hundreds of kilobase-scale hypomethylated domains, termed “large 
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hypo CG-DMRs”9,44. To identify this methylation feature in fetal tissues, for each tissue 
type, we merged tissue-specific CG-DMRs that are within 1kb and filtered for ones larger 
than 2kb, as previous described44. Consistent with previous results44, the large hypo CG-
DMRs (n=273-1,302), which comprise of 0.7%-1.6% the merged CG-DMRs, showed 
higher levels of H3K4me1 and H3K27ac compared with the typical smaller CG-DMRs, 
implying that these clusters of predicted fetal enhancers may represent tissue-specific 
super-enhancers54 (Fig. 4a-e). Indeed, 25-57% of the large hypo CG-DMRs overlapped 
with regions predicted as super-enhancers (Fig. 4f; Methods). Like super-enhancers, we 
found that a very large portion (58%-79%) of these large hypo CG-DMRs are intragenic 
(p-value < 0.001; Methods) and are significantly associated with genes enriched for 
tissue-related biological processes (false discovery rate < 0.01; Supplemental Table 8).  
These large hypo CG-DMR are different from another type of multi-kilobase 
DNA methylation feature called the DNA methylation valley (DMV; Methods)55. DMVs 
are generally ubiquitously lowly methylated in all tissues across developmental trajectory 
(Extended Data Fig. 8a-b). Large hypo CG-DMRs, in contrast, display striking 
spatiotemporal hypomethylation patterns (Extended Data Fig. 8a, c). Consistently, less 
than 4% of large hypo CG-DMRs overlapped with DMVs. Furthermore, we found that 
53-58% of the DMV-overlapped genes encoding TFs, much more than large hypo CG-
DMRs (8-17%; Extended Data Fig. 8d).  
 
Intragenic non-CG methylation 
A less well-understood form of cytosine DNA methylation found in mammal 
genomes is called non-CG methylation or mCH18. While mCH is only present at low 
levels in most adult tissues, it is the dominant form of cytosine methylation in human 
neurons18. While no mechanism is known to actively remove mCH, passive dilution can 
occur during cell replication18. Surprisingly, we found that mCH accumulates to 
detectable levels in nearly all fetal tissues as some point during their developmental 
trajectories; the timing varies in different tissues/organs (Fig. 5a). For example, three 
brain distinct region tissues showed different rates of mCH accumulation the timing of 
which correlates with their developmental maturation (lower expression of neural 
progenitor markers and higher expression of neuronal markers) in sequential order of 
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hindbrain, midbrain, and forebrain (Fig. 5a; Extended Data Fig. 9). mCH is preferentially 
deposited at 5’-CAG-3’ context in embryonic stem cells and at 5’-CAC-3’ context in 
adult tissues8–10,17–19. In all fetal tissues we found mCH enriched in the CAC context and 
its enrichment in this 3 base specificity further increased as the tissues mature, implying a 
similar DNMT3A-dependent mCH pathway in both fetal and adult tissues18 (Extended 
Data Fig. 10a). 
Intriguingly, mCH was not uniformly distributed across the genome of fetal 
tissues but preferentially accumulated at genomic regions that we termed as “mCH 
domains”; genomic locations showing higher mCH levels than their flanking sequences 
(Fig. 5b). In total, 384 mCH domains were identified, which averaged 255kb in length 
(Methods). Strikingly, 92% (355 out of 384) of mCH domains and 61% of the bases 
within them overlapped with annotated gene bodies (p-value < 0.001; Methods). 
Interestingly we found a highly significant fraction (22%) of the mCH domain genes (e.g. 
Pax3) encode transcription factors, many of which are known to be involved in tissue 
development/organogenesis (Fig. 5b; 128 out of the 581 genes, p-value < 0.001; 
Methods).  
To further explore the tissue and temporal specificity of mCH accumulation, we 
used k-means clustering to group mCH domains into 5 clusters based on methylation 
dynamics (Fig. 5b-c; Extended Data Fig. 10b; Methods). mCH domains in clusters 1 and 
3 acquire mCH in all tissues and are enriched for genes related to embryo development 
(Fig. 5c-e; Extended Data Fig. 10b; Supplemental Table 9). mCH accumulation in cluster 
4 is also observed in all tissues but is more pronounced than in clusters 1 and 3. 
Interestingly, the cluster 4 mCH domains were significantly enriched for genes involved 
with neuron differentiation functions (Fig. 5d-e). In contrast to these ubiquitous mCH 
domains, tissue-specific mCH domains were also found. Cluster 2 gains mCH mostly in 
heart where as those in cluster 5 show brain-specific mCH accumulation, overlapping 
genes that are enriched for functions related to axon guidance (Supplemental Table 9). 
As mCH accumulates in mCH domains at late developmental stages, the genes 
within tend to be repressed in their expression compared with genes outside mCH 
domains, especially by P0 (Fig. 5f; Extended Data Fig. 10c). Since mCH domains are 
enriched for TFs and other genes related to tissue/organ or embryo development, our data 
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suggests that mCH may be associated with silencing of the pathways of early fetal 
development. 
Interestingly, mCH domains showed enrichment for tissue-specific feDMRs 
compared to flanking regions (Fig. 5g). feDMRs in mCH domains tend to lose enhancer-
like chromatin signatures as development proceeded (decreasing enhancer score; 
Extended Data Fig. 10d). In addition, these feDMRs, in late stages, tend to become 
hypermethylated compare with ones outside mCH domains (Extended Data Fig. 10e). 
These observations indicate that mCH accumulation predicts the future silencing 
of regulatory elements, consistent with recently reported findings for human cerebral 
organoids56. Collectively, we found mutual associations between several mCH domains 
features including: mCH accumulation, enrichment for genes related to the tissues that 
acquire mCH, down-regulation of gene expression and enrichment of feDMRs. 
Delineating the mechanism(s) that drive these associations will provide new insights into 
mCH regulation and the potential involvement of non-CG methylation in transcriptional 
regulation. 
 
Conclusion 
In this study we describe the generation and analysis of a comprehensive collection of 
base-resolution, genome-wide maps of cytosine methylation for 12 fetal tissue types from 
8 distinct developmental stages of mouse embryogenesis. By integrating DNA 
methylation, histone modification and RNA sequencing data from the same tissue 
samples, we annotated millions of methylation variable elements including prediction of 
fetal enhancers and sets of transcription factors that bind them. The human counterparts 
of these fetal enhancers are tissue-specifically enriched for genetic risk loci associated 
with human diseases. Such enrichments suggest the possibility of generating mouse 
models of human diseases by introducing the specific alleles into feDMRs using genomic 
editing techniques57. Because of the temporal nature of these data, we uncovered 
surprisingly simple mCG dynamics at predicted DNA regulatory regions. During early 
stages of fetal development, methylation decreases at predicted fetal regulatory elements 
in all tissues until birth, after which time it dramatically rises. Since the tissues that we 
have investigated are composed by a variety of cell types, a fraction of the observed 
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dynamics potentially result from DNA methylation changes during the differentiation of 
individual cell types and/or the changing cell type composition during development. In 
spite of the tissue heterogeneity, such dynamics suggest a plausible regulatory principal 
whereby stable repressive mCG is removed to enable more rapid, flexible modes of gene 
regulation (e.g. histone modification/open chromatin). Also, our findings extend current 
knowledge of methylation in a non-CG context, an understudied type of DNA 
methylation. We observed that during fetal development there is preferential 
accumulation of mCH tissue-specifically at genomic locations, each hundreds of 
kilobases in size, a novel genomic feature we termed “mCH domains”. Genes that lie in 
mCH domains become down-regulated in their expression as mCH further accumulates 
during the later stages of fetal development. Though its function remains debatable, in 
vivo and in vitro studies indicated that mCH directly increases the binding affinity of 
MeCP221–23, mutation of which leads to Rett Syndrome. Gene-rich mCH domains are 
likely enriched for yet to be discovered mCH binding proteins, which, like MeCP2, may 
be involved recruiting transcriptional repressor complexes, promoting the observed gene 
repression. Our study highlights the power of temporal tissue epigenome maps to uncover 
regulatory element dynamics in fetal tissues during in utero development. These 
spatiotemporal epigenomic datasets provide a valuable resource for studies of 
fundamental questions about gene regulation during mammalian tissue/organ 
development as well as knowledge about the possible origins of human developmental 
diseases. 
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Supplemental Note - mCG landscape remodeling in fetal liver 
Distinct from the hypermethylated genome of all other tissues, the liver genome 
underwent drastic global demethylation from E11.5 to E14.5, and remained 
hypomethylated till E16.5, after which it returned to hypermethylated state at P0 (Fig. 
1B). The hypomethylated liver genome, present during E12.5 to E16.5, displayed a 
partially methylated domains (PMDs) signature, a methylation feature previously 
observed in human cultured cell lines8,29, pancreas9, placenta30 and cancer samples31,32. 
PMDs are large genomic regions (typically greater than 100kb) that are lowly CG 
methylated (Extended Data Fig. 1A). We systematically identified PMDs in liver samples 
from all stages (Methods). Strikingly, from E14.5 to E16.5, PMDs covered more than 
half of the genome and the coverage shrunk dramatically afterwards (Extended Data Fig. 
1B). We found that PMDs identified in E15.5 displayed hypomethylation in all liver 
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samples and covered almost all PMDs from other stages (Extended Data Fig. 1C-D). 
These results indicate that the PMDs identified at different fetal stages are essentially 
identical and the different PMDs calls were due to various signal-to-noise ratios. 
Therefore, we defined the PMDs identified in E15.5 liver as liver PMDs (n = 4,578; 
average size = 338kb). 
Mouse liver PMDs share all molecular signatures of the PMDs identified in 
human fibroblast cell lines, normal and cancer tissues8,9,31,32: First, mouse PMDs are 
enriched for H3K9me3 and H3K27me3 and are depleted of H3K27ac (Extended Data 
Fig. 1E). Second, mouse PMDs tend to be replicated during the later stages of the cell 
cycle and strongly overlap with lamina-associated domains (Extended Data Fig. 1F; p-
value < 0.001; permutation test; Methods). Furthermore, we found that genes overlapping 
with mouse PMDs tend to have lower expression compared to genes outside PMDs, 
which was also reported by Schultz et al for human pancreas9. These shared properties 
indicate that human and mouse PMDs are likely identical genome feature and their 
presence may be due to similar mechanism, likely the failure of mCG maintenance in 
rapidly dividing cells31.  
The presence of PMDs in fetal liver coincides with hematopoiesis61,62. 
Hematopoiesis initiates at E11.5, while liver genome remains hypermethylated (Fig. 1B). 
Then, hematopoietic expansion occurs between E12.5 and E14.5, during which the liver 
genome underwent demethylation and PMDs became evident (Fig. 1B; Extended Data 
Fig. 1B and D). The increasing number of rapidly dividing cells during this expansion 
period may explain the formation of PMDs. After E15.5, the hematopoiesis starts to 
disappear although the “liver tissue” genome is not fully remethylated until P0 (Extended 
Data Fig. 1B).  
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Figure 1 
 
Figure 1. Annotation of methylation variable regulatory elements in developing 
mouse tissues. 
a, Tissue samples (green) profiled in this study. Grey cells mark the tissues and stages 
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that were not sampled because either the tissue is not yet formed or it was not possible to 
obtain enough material for the experiment, or the tissue-type was too heterogeneous to 
obtain informative data.  
b, Genome-wide CG methylation (mCG) levels of each tissue across their developmental 
trajectories. The data point of adult forebrain (postnatal 6 week frontal cortex) is from 
Lister et al10. 
c, Example of a CG differentially methylated region (CG-DMR) in the body of the Satb2 
gene. Top two tracks show the gene annotation and the locations of CG islands (CGIs), 
which are followed by mCG tracks and a CG-DMR track. Gold ticks represent 
methylated CG sites and their heights indicate the mCG level, ranging from 0 to 1. Ticks 
on the forward DNA strand are projected upward and ticks on the reverse DNA strand are 
projected downward. 
d, Fetal CG-DMRs identified in this study encompass the majority of the adults CG-
DMRs from a previous study of adult tissues6. The numbers related to fetal CG-DMR in 
this study are shown without parenthesis, whereas the numbers in parenthesis are related 
to adult tissue CG-DMRs.  
e, Distance of CG-DMRs to the nearest transcription start sites (TSSs).  
f, Categorization of CG-DMRs. “proximal CG-DMRs” are CG-DMRs that are 
overlapped with promoters, CG islands (CGIs) or CGI shores. The remaining CG-DMRs 
are defined as “distal CG-DMRs”. fetal enhancer-linked CG-DMRs (feDMRs) are those 
predicted to show enhancer activity using REPTILE algorithm27, which contain 415,227 
distal feDMRs and 72,140 proximal feDMRs. CG-DMRs within 1kb to distal feDMRs 
are “flanking distal CG-DMRs”. Of the remaining distal CG-DMRs, we defined “primed 
distal feDMRs” as those showing strong hypomethylation patterns (mCG difference >= 
0.3) and also primed enhancer-like chromatin signatures. The remaining CG-DMRs are 
unexplained distal CG-DMRs” (unxDMRs), whose functions are unknown. unxDMRs 
are further stratified based on their overlap with transposons: transposal element 
overlapping unxDMRs (“te-unxDMRs”) and transposal element non-overlapping 
unxDMRs (“nte-unxDMRs”). The number of CG-DMRs assigned to each group is shown 
in the parentheses. See Methods for details. 
g, Conservation (phyloP) score of promoters and different categories of distal CG-DMRs. 
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h, Tissue-specific feDMRs are enriched in GWAS SNPs associated with tissue/organ 
specific functions and tissue-related disease states. 
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Figure 2 
 
Figure 2. Tissue-specific CG-DMRs undergo continuous demethylation during 
embryogenesis and remethylation after birth. 
a, CG methylation (mCG) level of tissue-specific CG-DMRs. The number under each 
heatmap indicates the number of tissue-specific CG-DMRs. mCG data from adult (AD) 
forebrain was approximated using data from postnatal 6 week frontal cortex from Lister 
et al10. 
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b, The numbers of loss-of-mCG events (blue) and gain-of-mCG events (red) in tissue-
specific CG-DMRs for each fetal stage interval. We defined one loss-of-mCG (gain-of-
mCG) event as the decrease (increase) of at least 0.1 in mCG level of one CG-DMR for 
one fetal stage interval. 
c-d, Fraction of tissue-specific CG-DMRs that undergo lost-of-mCG (blue) and gain-of-
mCG (red) during development. The blue (loss-of-mCG) or red (gain-of-mCG) line 
shows the aggregated values over all non-liver tissues, whereas grey lines show the data 
for each tissue type. 
e, mCG and H3K27ac dynamics of forebrain-specific CG-DMRs. Frontal cortex 
methylomes from postnatal 1, 2, 4, 6 weeks (P1w to P6w) were compared with data from 
adult forebrain. Forebrain-specific CG-DMRs were clustered into 8 groups (see Methods 
for details). 
f, Relationship between mCG level and enrichment of H3K27ac in tissue-specific CG-
DMRs. For each tissue type, tissue-specific CG-DMRs were first grouped into three 
categories (L: low; M: median; H: high) based on their mCG level. Then, the fraction of 
tissue-specific CG-DMRs from each category that showed different levels of H3K27ac 
enrichment was quantified. This panel shows the results of all non-liver tissues.  
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Figure 3 
 
Figure 3. Association between CG methylation (mCG) and the expression patterns 
of coexpression modules (CEMs). 
a, Expression of the 2,500 most variable genes in all tissue samples. Tissue samples were 
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grouped using hierarchical clustering. Gene expression is measured by log10 (TPM+1) 
(transcripts per million) z-score. Black box highlights a group of co-expressed genes that 
are highly expressed in neuronal tissues. 
b, 33 CEMs identified in WGCNA and their eigengene expression. The CEMs related to 
the next panel (c) are bolded. 
c, The most enriched gene ontology (Biological Process) terms of genes in four 
representative modules.  
d, Correlation of the tissue-specific eigengene expression (orange) for each 
developmental stage with the average mCG level (blue) and the average enhancer score 
(red) for feDMRs linked to the genes in the CEM32. The mCG levels (enhancer score) of 
each feDMR was normalized by dividing the genome-wide average mCG level (enhancer 
score) and then transformed to z-scores (See Methods for details). Pearson correlation 
coefficient (r) was calculated.  
e, Pearson correlation coefficients of mCG (blue) or enhancer score (red) of neighboring 
feDMRs with tissue-specific eigengene expression across all 33 CEMs on all stages. P-
values were obtained by testing the median of the Pearson correlation coefficients against 
the median of the shuffled (grey) using two-tailed Mann-Whitney test. 
f-g, Similar to (d), correlation of temporal eigengene expression for CEM29 (f) and 
CEM12 (g) with the average mCG level and the average enhancer score of neighboring 
feDMRs. 
h, Similar to (e), Pearson correlation coefficients of mCG and enhancer score with 
temporal epigengene expression across all CEMs and all tissue types, excluding liver. See 
Methods for details. 
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Figure 4 
 
Figure 4. Large hypo CG-DMRs are enriched for super-enhancers. 
a, Examples of large hypo CG-DMRs. 
b-c, H3K27ac (b) and H3K4me1 (c) enrichment in large hypo CG-DMRs (red) and the 
rest of CG-DMRs (green) at all developmental stages across all tissue types except liver. 
d-e, H3K27ac (d) and H3K4me1 (e) enrichment in heart-specific large hypo CG-DMRs 
(red) and the rest of heart-specific CG-DMRs (green) in heart tissue from all 
developmental stages. 
f, Number of large hypo CG-DMRs identified in each tissue type and the percentage that 
overlap with super-enhancers (red).  
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Figure 5 
 
Figure 5. mCH accumulation predicts reduced gene expression. 
a, Genome-wide non-CG methylation (mCH) levels for each tissue across their 
developmental trajectories. The adult (AD) forebrain data (postnatal 6 week frontal 
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cortex) is from Lister et al10. 
b, An example of a mCH domain. Enriched for mCH accumulation determined by 
comparison to flanking regions. 
c, K-means clustering identification of 384 mCH domains clustered into 5 groups based 
on the tissue-specific mCH accumulation. Heatmap showing the methylation profiling of 
mCH domains and flanking genomic regions (100kb upstream and 100kb downstream).  
d, Number of genes overlapping mCH domains in each of 5 groups. Dark blue bars 
indicate the number of genes encode transcription factors in mCH domains. Examples of 
genes located within mCH domains are listed on the right. 
e, The most enriched gene ontology (Biological Process) terms for genes that lie within 
mCH domains for each cluster. 
f, Expression dynamics of genes within mCH domains relative to the other genes. Z-
scores were calculated for each gene across development and each line shows the mean 
value of mCH overlapping genes for each cluster. 
g, Tissue-specific enrichment of feDMRs in mCH domains. Each mCH domain was 
divided into 10 bins and its flanking regions included ten 10kb upstream bins and ten 
10kb downstream bins. Line plots show the fraction of bases in each bin that are 
overlapped with tissue-specific feDMRs. A list of tissues in each plot indicates wthere 
feDMRs are enriched in mCH domains compared to flanking regions (from the most 
enriched to the least enriched). 
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Extended Data Figure 1 
 
Extended Data Figure 1. Global hypomethylation in fetal liver 
a, Example of a partially methylated domain (PMDs) in developing mouse fetal liver. 
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The PMD location is marked by a red bar. 
b, The total bases that PMDs encompass in liver at different developmental stages. 
c, Percentage of bases in the PMDs identified in each of the liver samples (E12.5 liver, 
E13.5 liver etc) that are also within the PMDs identified in E15.5 liver sample. 
d, Average mCG level (mCG/CG) of PMDs and flanking regions (+/-100kb) in liver 
samples from different developmental stages. 
e, Histone modification profiles for H3K9me3 (top), H3K27me3 (middle) and H3K27ac 
(bottom) within PMDs and flanking regions (+/-100kb) in liver samples from different 
developmental stages.  
f, Replication timing profiling of PMDs and flanking regions (+/-100kb). The values 
indicate the tendency to be replicated at an earlier stage in the cell cycle. 
g, Expression of genes overlapping PMDs and flanking regions (+/-100kb) (left) 
compared with those with no PMD overlap (right). Two plots on the bottom show the 
data from a validation dataset, containing RNA-seq data generated using different 
protocol on the matched tissues. 
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Extended Data Figure 2 
 
Extended Data Figure 2. Categorization of CG-DMRs 
a, Genomic distribution of proximal CG-DMRs. 
b, Evolutionary conservation of proximal CG-DMRs overlapping with: CG islands 
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(CGI), CGI shores, CGI promoters and non-CGI promoters. phyloP score was used to 
measure the degree of conservation. 
c, Chromatin signatures of fetal enhancer-linked CG-DMRs in E11.5 heart. The 
aggregate line plots show the average histone modification and mCG profiles of +/- 5kb 
regions centered at CG-DMR centers.  
d, Table summarizing the definition and number of various CG-DMR categories. Note 
that categories in the table are mutually exclusive. 
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Extended Data Figure 3 
 
Extended Data Figure 3. Fetal-enhancer-linked CG-DMRs (feDMRs) 
a, The overlap between feDMRs identified in this study and the enhancers predicted in 
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Yue et al37. Numbers in parenthesis indicate the counts of enhancers from Yue et al, 
whereas the remaining numbers denote the counts of feDMRs.  
b, Experimental validation results of the feDMR-overlapping elements from VISTA 
enhancer browser38. Different enhancer score thresholds were used for calling feDMRs 
for each tissue at fetal stage E11.5. Each pie shows the fraction of elements that were 
experimentally validated as active enhancers in matched tissue (red) or any tissue 
(orange) or as inactive enhancers (white) at fetal state E11.5. 
c, Enrichment of transcription factor binding motifs in feDMRs of different tissue types. 
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Extended Data Figure 4 
 
Extended Data Figure 4. Characterization of primed distal feDMRs and unxDMRs 
a, CG methylation (mCG) level of all primed distal fetal enhancer-linked CG-DMRs 
(feDMRs) in all non-liver tissues. Each row in the heatmap is one tissue sample and each 
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column corresponds to one primed distal feDMR. Both rows and columns were clustered 
using hierarchical clustering. Colors bars indicate the tissue types and developmental 
stages of samples, respectively. 
b, mCG (left) and histone modification (right) signatures of primed distal feDMRs (blue) 
and feDMRs (red). Boxplots show the median and quantiles of the values in all non-liver 
tissues. 
c, Number of enriched transcription factor binding motifs only in feDMRs (red), only in 
primed distal feDMRs (orange), both (dark red) and none (grey). Only the motifs linked 
to expressed transcription factors (transcripts per million, TPM >= 10) were included. 
d-e, Similar to (a), heatmaps showing the mCG levels of unexplained CG-DMRs, 
including te-unxDMRs (d) and nte-unxDMRs (e). 
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Extended Data Figure 5 
 
Extended Data Figure 5. mCG dynamics of tissue-specific CG-DMRs 
 a, Fraction of tissue-specific CG-DMRs showing loss-of-mCG (blue) or gain-of-mCG 
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(red) for each fetal stage. Loss-of-mCG (gain-of-mCG) event is defined as an increase 
(decrease) of mCG of at least 0.1. 
b, Composition of tissue-specific CG-DMRs. 
c, Percentage of loss-of-mCG events for each fetal stage. 
d, Percentage of gain-of-mCG events for each fetal stage. 
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Extended Data Figure 6 
 
Extended Data Figure 6. Link between methylation dynamics and histone 
modifications at tissue-specific CG-DMRs 
a, Fraction of tissue-specific CG-DMRs that are heavily CG methylated (mCG level > 
0.6).  
b, RNA abundance of genes involved in DNA methylation pathways, measured by 
transcripts per million (TPM). 
c, Normalized H3K27ac signals in different clusters. 
d, Dynamic mCG level of forebrain-specific CG-DMRs. Grey lines show the mean 
methylation levels of CG-DMRs in different clusters. Blue line is the mean of all clusters 
(grey lines). 
  
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/166744doi: bioRxiv preprint first posted online Jul. 21, 2017; 
	 37 
Extended Data Figure 7 
 
Extended Data Figure 7. WGCNA identification of co-expression modules 
a, The scale free topology model fit (R2) (top) and the mean connectivity of the 
coexpression network (bottom) given different soft-thresholding powers. These two plots 
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show how thresholds were chosen for weighted gene co-expression network analysis 
(WGCNA). Blue horizontal line indicates the model fit cutoff (R2 = 0.8). A soft threshold 
= 5 was chosen to construct the co-expression network because it is first threshold value 
where the model fit is greater than 0.8. 
b-c, Expression of genes in CEM12 (b) and CEM32 (c). Each row is a gene in certain 
module and the transcripts per million (TPM) z-scores were calculated along each row. 
d, Top enriched ontology terms of genes in co-expression modules. 
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Extended Data Figure 8 
Extended Data Figure 8. Comparing large hypo CG-DMRs and DNA methylation 
valleys (DMVs). 
a, CG methylation (mCG) level of large hypo CG-DMRs (top) or DMVs (bottom) in all 
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non-liver tissues. Both rows and columns were clustered using hierarchical clustering. 
Colored bars indicate the tissue types and developmental stages of samples, respectively. 
Heatmap shows the data of merged large hypo CG-DMRs (DMVs) for predictions from 
all tissue samples. See Methods for details. 
b, Fraction of large hypo CG-DMRs (left) or DMVs (right) that undergo lost-of-mCG 
(top, blue) and gain-of-mCG (bottom, red) during development. The blue (loss-of-mCG) 
or red (gain-of-mCG) line shows the aggregated values over all non-liver tissues, whereas 
grey lines show the data for each tissue type. 
c, Average mCG level of DMVs identified in each tissue type. 
d, Number of genes overlapping with large hypo CG-DMRs (left) or DMVs (right). Dark 
blue indicates genes encoding transcription factors (TFs). 
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Extended Data Figure 9 
 
Extended Data Figure 9. Expression of neural progenitor and neuronal markers in 
different brain regions. 
a, Expression of neural progenitor markers, Nes 58 and Sox259. TPM – transcripts per 
million mapped reads. 
b, Expression of several neuronal markers from Svendsen et al60.  
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Extended Data Figure 10 
 
Extended Data Figure 10. Non-CG methylation accumulation in fetal tissues 
a, Sequence context preference for non-CG methylation (mCH).  
b, Grouping mCH domains into 5 clusters based on the dynamics of methylation 
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accumulation. The heatmap shows normalized methylation levels of mCH domains and 
flanking genomic regions (up to 100kb upstream and 100kb downstream). mCH in the 
adult (AD) forebrain was approximated using data of frontal cortex from 6-week-old 
mice. 
c, Average enhancer score dynamics of feDMRs within mCH domains. Z-scores were 
calculated for each feDMR across development and each line shows the mean value of 
the mCH domains overlapping feDMRs for each cluster.  
d, Enrichment of tissue-specific feDMRs that showed different CG methylation levels in 
mCH domains. Colors (from blue to red) denote the stages where the mCG level was 
calculated. 
f, The expression of genes in mCH domains at P0 relative to the expression dynamics of 
genes outside mCH domains. Each circle corresponds to the value given one mCH 
domain cluster and one tissue. Red horizontal line indicates the median, which was tested 
against 0 using one-sided Wilcoxon signed-rank test. 
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Methods 
Data Availability 
All whole-genome bisulfite sequencing (WGBS) data from mouse embryonic 
tissues are available at the ENCODE portal (https://www.encodeproject.org/) and also 
deposited in the NCBI Gene Expression Omnibus (GEO) (Supplemental Table 1). The 
additional RNA-seq dataset of forebrain, midbrain, hindbrain and liver is available at the 
NCBI Gene Expression Omnibus (GEO) under accession GSE100685. All other data 
used in this study, including chromatin immunoprecipitation sequencing (ChIP-seq), 
RNA-seq and additional WGBS data, are available at the ENCODE portal and/or GEO 
(Supplemental Table 2).  
 
Code availability 
Custom code used for this study is available upon request. This work used 
computation resource from the Extreme Science and Engineering Discovery Environment 
(XSEDE)63. 
 
Abbreviations 
• AD: adult 
• CEM: co-expression module 
• mC: cytosine DNA methylation 
• mCG: CG methylation 
• mCH: non-CG methylation 
• TF: transcription factor 
• H3K4me1: Histone 3 lysine 4 monomethylation 
• H3K4me3: Histone 3 lysine 4 trimethylation) 
• H3K27me3: Histone 3 lysine 27 trimethylation 
• H3K27ac: Histone 3 lysine 27 acetylation 
• WGBS: whole-genome bisulfite sequencing 
• REPTILE: Regulatory Element Prediction based on TIssue-specific Local Epigenetic 
marks 
• GWAS: genome-wide association study 
• SNP: single nucleotide polymorphism 
• TPM: transcripts per million 
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• WGCNA: weighted gene co-expression network analysis 
• RPKM: Reads Per Kilobase per Million mapped reads 
 
Genomic features 
• CG-DMR: differentially CG methylation region 
• feDMR: fetal enhancer linked CG-DMR 
• fd-feDMR: flanking distal feDMR 
• pd-feDMR: poised distal feDMR 
• unxDMR: unexplained CG-DMR 
• te-unxDMR: transposable element overlapping unxDMR 
• nte-unxDMR: non transposable element overlapping unxDMR 
• TSS: transcription start sites 
• CGI: CpG island 
• DMV: DNA methylation valley 
• PMD: partially methylated domain 
• AD-A enhancer: adult active enhancer 
• AD-V enhancer: adult vestigial enhancer 
 
Tissues/organs 
• FB: forebrain 
• MB: midbrain 
• HB: hindbrain 
• NT: neural tube 
• HT: heart 
• CF: craniofacial 
• LM: limb 
• KD: kidney  
• LG: lung 
• ST: stomach 
• IT: intestine 
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• LV: liver 
 
Tissue Collection 
All animal work was reviewed and approved by the Lawrence Berkeley National 
Laboratory Animal Welfare and Research Committee or the University of California, 
Davis Institutional Animal Care and Use Committee. 
Mouse fetal tissues were dissected from embryos of different developmental 
stages from female C57Bl/6N Mus musculus animals. Animals, used for obtaining tissue 
materials from E14.5 and P0 stages, were purchased from both Charles River 
Laboratories (C57BL/6NCrl strain) and Taconic Biosciences (C57BL/6NTac strain). For 
tissues of remaining developmental stages, animals (C57BL/6NCrl strain) were 
purchased from Charles River Laboratories. The number of embryos or P0 pups collected 
was determined by whether the materials were sufficient for genomic assay, and was not 
based on statistical considerations. 15-120 embryos/pups were collected for each 
replicate of each tissue of each stage. 
 
Tissue Excision And Fixation 
See Supplemental File 1-2 for details. 
 
MethylC-seq Library Construction and Sequencing 
MethyC-seq libraries were constructed as previously described9 and a detailed 
protocol is available64. An Illumina HiSeq 2500 system was used for all whole genome 
bisulfite sequencing (WGBS) using either 100 or 130 base single-ended reads.  
 
Mouse Reference Genome Construction 
For all analyses in this study, we used mm10 as the reference genome, which 
includes 19 autosomes and two sex chromosomes (corresponding to the “mm10-minimal” 
reference in ENCODE portal, https://www.encodeproject.org/). The fasta files of mm10 
were downloaded from UCSC genome browser (Jun 9 2013)65. 
 
WGBS Data Processing 
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All WGBS data were mapped to the mm10 mouse reference genome as 
previously described66. WGBS processing includes mapping of the bisulfite-treated phage 
lambda genome spike-in as control to estimate sodium bisulfite non-conversion rate. This 
pipeline called methylpy is available on github (https://github.com/yupenghe/methylpy). 
Briefly, cytosines within WGBS reads were first computationally converted to thymines. 
The converted reads were then aligned by bowtie (1.0.0) onto the forward strand of C-T 
converted reference genome and the reversed strand of G-A converted reference genome, 
separately. We filtered out reads that were not uniquely mapped or were mapped to both 
computationally converted genomes. Next, PCR duplicate reads were removed. Lastly, 
methylpy counts the methylated basecalls (cytosines) and unmethylated basecalls 
(thymines) for each cytosine position in the corresponding reference genome sequence 
(mm10 or lambda). 
 
Calculation of Methylation Level 
Methylation level was computed to measure the intensity and degree of DNA 
methylation of single cytosines or larger genomic regions. The methylation level is 
defined as the ratio of the sum of methylated basecall counts over the sum of both 
methylated and unmethylated basecall counts at one cytosine or across sites in a given 
region67 subtracting the sodium bisulfite non-conversion rate. The sodium bisulfite non-
conversion rate is defined as the methylation level of the bisulfite-treated lambda genome. 
We calculated this metric for cytosines in both CG context and CH contexts (H=A, 
C or T). The former is called the CG methylation (mCG) level or mCG level while the 
latter is called the CH methylation (mCH) level or mCH level.  
 
ChIP-seq Data Processing 
ChIP-seq data were processed using the ENCODE uniform processing pipeline 
for ChIP-seq. In brief, Illumina reads were first mapped to the mm10 reference using 
bwa68 (version 0.7.10) with parameters “-q 5 -l 32 -k 2”. Next, the Picard tool 
(http://broadinstitute.github.io/picard/, version 1.92) was used to remove PCR duplicates 
using the following parameters: “REMOVE_DUPLICATES=true”.  
For each histone modification mark, we represented it as continuous enrichment 
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values of 100bp bins across the genome. The enrichment was defined as the RPKM 
(Reads Per Kilobase per Million mapped reads) after subtracting ChIP input. The 
enrichment across the genome was calculated using bamCompare in Deeptools269 using 
options “--binSize 100 --normalizeUsingRPKM --extendReads 300 --ratio subtract“. For 
the ChIP-seq data of EP300, we used MACS70 (1.4.2) to call peaks using default 
parameters.  
 
RNA-seq Data 
Processed RNA-seq data for all fetal tissues, from all stages was downloaded 
from the ENCODE portal (https://www.encodeproject.org/; Supplemental Table S2).  
To further validate our findings regarding transcriptomes generated across 
laboratories (Wold and Ecker), we generated an additional two replicates of RNA-seq 
data for fetal forebrain, midbrain, hindbrain and liver tissues. We first extracted total 
RNA using RNeasy Lipid tissue mini kit from Qiagen (cat no.#74804). Then, we used 
Truseq Stranded mRNA LT kit (Illumina, RS-122-2101 and RS-122-2102) to constructed 
stranded RNA-seq libraries on 4ug of the extracted total RNA. An Illumina HiSeq 2500 
was used to sequence the libraries and generate 130 bases single-ended reads.  
 
RNA-seq Data Processing and Gene Expression Quantification 
RNA-seq data was processed using the ENCODE RNA-seq uniform processing 
pipeline. Briefly, RNA-seq reads were mapped to the mm10 mouse reference using 
STAR71 aligner (version 2.4.0k) with Gencode M4 annotation72. We quantified gene 
expression levels using RSEM (version 1.2.23)73, expressed as transcripts per million 
(TPM). For all downstream analyses, we filtered out non-expressed genes and only 
retained genes that showed non-zero TPM in at least 10% of samples. 
 
Genomic Features of Mouse Reference Genome 
We used GENCODE M472 gene annotation in this study. CG island (CGI) 
annotation was downloaded from UCSC genome browser (Sep 5, 2016)65. CGI shores are 
defined as the upstream 2kb and downstream 2kb regions along CGIs. Promoters are 
defined as regions from - 2.5kb to +2.5kb around transcription start sites (TSSs). CGI 
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promoters are defined as those overlapping with CGIs while the remaining promoters are 
called non-CGI promoters.  
We also obtained a list of mappable transposable elements (TEs) using the below 
procedure. RepeatMasker annotation of the mm10 mouse genome was downloaded from 
UCSC genome browser (Sep 12, 2016)65. The annotation includes 5,138,231 repeats. We 
acquired the transposon annotation by selecting only the repeats belonging to one of the 
below repeat classes (repClass): “DNA”, “SINE”, “LTR” or “LINE”. Then, we excluded 
any repeat elements with a question mark in their name (repName), class (repClass) or 
family (repFamily). For the remaining 3,643,962 transposons, we further filtered out 
elements that contained less than 2 CG sites or cases where less than 60% of CG sites 
within were covered by at least 10 reads across all samples when the data of two 
replicates were combined. Finally, we utilized the remaining set of 1,688,189 mappable 
transposable elements for analyses in this study.  
 
CG Differentially Methylated Region (CG-DMRs) 
We identified CG-DMRs using methylpy (https://github.com/yupenghe/methylpy) 
as previously described66. Briefly, we first called CG differentially methylated sites (CG-
DMSs) and then merged them into blocks if they both showed similar sample-specific 
methylation patterns and were within 250bp. Last, we filtered out blocks containing less 
than three CG-DMSs. In this procedure, we combined the data from the two biological 
replicates for all tissues, excluding liver samples due to global hypomethylation of the 
genome.  
 We overlapped the resulting fetal tissue CG-DMRs with CG-DMRs previously 
identified in Hon et al12 using “intersectBed” from bedtools74. The mm9 coordinates of 
the CG-DMRs from Hon et al. were first, mapped to mm10 using liftOver65 with default 
parameters. Overlap of CG-DMRs is defined as a CG-DMR with at least one base 
overlap with another CG-DMR when comparing genomic coordinates between lists.  
 
Identification of Tissue-Specific CG-DMRs 
For each fetal tissue type, we defined tissue-specific CG-DMRs as those that 
showed hypomethylation in a tissue sample from any fetal stage (E10.5 to P0). 
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Hypomethylation is only meaningful with a baseline, thus we used an outlier detection 
algorithm75 to defined the baseline mCG level of each CG-DMR across tissue samples 
using the mean of the “bulk”, which is defined as the value for the narrowest mCG level 
interval that includes at least half of all samples. Specifically, 𝑥!!  is the mCG level of CG-
DMR 𝑖 (𝑖 = 1,… ,𝑀) in tissue sample 𝑠 (𝑠 = 1,… ,𝑁). Assuming the samples are 
ordered such that 𝑥!! ≤ 𝑥!! … ≤ 𝑥!! … ≤ 𝑥!! , the baseline is defined as the 𝑏! =𝑥!!!! !/!!!! , where 𝑎 is the sample index such that 𝑥!! !/!! − 𝑥!!  is minimized, i.e. 𝑎 = 𝑎𝑟𝑔𝑚𝑖𝑛(𝑥!! !/!! − 𝑥!!). 𝑁/2  is defined as the smallest integer that is greater than 𝑁/2. Lastly, we defined hypomethylated samples as samples in which the mCG level at 
CG-DMR 𝑖 is at least 0.3 smaller than baseline 𝑏!, i.e. {𝑠| 𝑥!! − 𝑏! ≤ −0.3}. Then, CG-
DMR 𝑖 is specific to these tissues. Liver data was not included in this analysis and we 
excluded CG-DMRs that had zero coverage in any of the non-liver samples. In total, only 
402 (~0.02%) CG-DMRs were filtered out.  
 
Linking CG-DMRs with Genes 
We linked CG-DMRs to their putative target genes based on genomic distance. 
First, we only considered expressed genes, which showed non-zero TPM in at least 10% 
of all fetal tissue samples. Next, we obtained coordinates for transcriptional start sites 
(TSSs) of the expressed genes and paired each CG-DMR with the closest TSS using 
“closestBed” from bedtools74. In this way, we inferred a target gene for each CG-DMR; 
these gene/TSS associations were used in all subsequent analyses in this study. 
 
Predicting Fetal Enhancer-linked CG-DMRs (feDMRs) 
The REPTILE33 algorithm was used to identify the CG-DMRs that showed enhancer-like 
chromatin signatures. We called these fetal enhancer-like CG-DMRs or feDMRs. 
REPTILE uses a random forest classifier to learn and then distinguish the epigenomic 
signatures of enhancers and genomic background. One unique feature of REPTILE is that 
by incorporating the data of additional samples (as outgroup/reference), it is able to 
employ epigenomic variation information to improve enhancer prediction. In this study, 
REPTILE was run using input data from CG methylation (mCG) and six histone marks 
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(H3K4me1, H3K4me2, H3K4me3, H3K27ac, H3K27me3 and H3K9ac).  
A REPTILE enhancer model was trained as previously described33. Briefly, CG-
DMRs were called across the methylomes of mouse embryonic stem cells (mESCs) and 
all eight E11.5 mouse tissues. CG-DMRs were required to contain at least 2 CG-DMSs 
and they were extended 150bp in each direction (5’ and 3’). The REPTILE model was 
trained on the mESC data using E11.5 mouse tissues as outgroup. Data from mCG and 
six histone modifications are available for these samples. The training dataset consists of 
5000 positive instances (putative known enhancers) and 35,000 negative instances. 
Positives were 2kb regions centered at the summits of top 5,000 EP300 peaks in mESCs. 
Negatives include randomly chosen 5,000 promoters and 30,000 2kb genomic bins. The 
bins have no overlap with any positives or promoters. REPTILE learned the chromatin 
signatures that distinguish positive instances from negative instances. 
Next, using this enhancer model, we applied REPTILE to delineate feDMRs from 
the 1,808,810 CG-DMRs identified across all non-liver tissues. feDMRs were predicted 
for each sample based on data from mCG and six core histone marks, while the 
remaining non-liver samples were used as an outgroup. In REPTILE, the random forest 
classifier for CG-DMR assigns a confidence score ranging from 0.0 to 1.0 to each CG-
DMR in each sample. This score corresponds to the fraction of decision trees in the 
random forest model that vote in favor of the CG-DMR to be an enhancer. Previous 
benchmarks showed that the higher the score, the more likely that a CG-DMR shows 
enhancer activity33. We named this confidence score as the enhancer score. For each 
tissue sample, feDMRs are defined as CG-DMRs with enhancer score greater than 0.3. 
feDMRs were also defined for each tissue type as the CG-DMRs that were identified as 
an feDMR in at least one tissue sample of that tissue type. For example, if a CG-DMR 
was predicted as an feDMR only in E14.5 forebrain, it was classified as a forebrain-
specific feDMR. 
We overlapped the feDMRs with putative enhancers from Yue et al37. We utilized 
a set of coordinates identifying the center base position of putative enhancers for each of 
the tissues and cell types from 
http://yuelab.org/mouseENCODE/predicted_enhancer_mouse.tar.gz. Next, we defined 
putative enhancers as +/- 1kb regions around the centers. Putative enhancers from 
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different tissues and cells types were combined and merged if they overlapped. The 
merged putative enhancers (mm9) were then mapped to the mm10 reference using 
liftOver65. Finally, “intersectBed” from bedtools74 were used to overlap feDMRs with 
these putative enhancers. 
 
Enhancer Score and in vivo Enhancer Activity 
To estimate the likelihood that an feDMR with a certain enhancer score actually 
displays enhancer activity in vivo, we utilized enhancer data set from the VISTA 
enhancer browser38. Using the DNA elements in VISTA enhancer browser (VISTA 
elements), we validated feDMRs identified in six E11.5 tissues (forebrain, midbrain, 
hindbrain, heart, limb and neural tube), where at least 30 validated VISTA elements 
(enhancers) are available. Specifically, for each E11.5 tissue, we first overlapped 
feDMRs predicted in that tissue with VISTA elements and identified VISTA elements 
that fully contained at least one feDMR. Then, we calculated the fraction of feDMR 
overlapping VISTA elements that displayed enhancer activity in the predicted tissue, any 
tissue(s) as well as those that did not display enhancer activity in any tissue.  
 
Enriched Transcription Factor (TF) Binding Motifs in Tissue-Specific feDMRs 
To identify TF motifs enriched in feDMRs, we scanned the genome to delineate 
TF motif occurrences as previously described46. Briefly, we utilized TF binding position 
weight matrices (PWMs) from the MEME motif database (v11, 2014 Jan 23. motif sets 
chen2008, hallikas2006, homeodomain, JASPAR_CORE_2014_vertebrates, jolma2010, 
jolma2013, macisaac_theme.v1, uniprobe_mouse, wei2010_mouse_mw, 
wei2010_mouse_pbm, zhao2011). Then, FIMO76 was used to scanned the genome to 
identify TF motif occurrences using options “--output-pthresh 1E-5 --max-stored-scores 
500000”. 
 Next, we performed a hypergeometric test to identify significant motif 
enrichments. For each tissue type, we calculated the motif enrichment for feDMRs in that 
tissue (foreground) against a list of feDMRs identified for other tissues not overlapping 
with the foreground tissue list. For this analysis, we extended the average size of both 
foreground and background feDMRs to 400bp to avoid bias due to size differences. For a 
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given tissue 𝑡, the total number of foreground and background feDMRs is 𝑁!,! and 𝑁!,!, 
respectively, and 𝑁! = 𝑁!,! + 𝑁!,! is the total number of feDMRs. For a given TF binding 
motif 𝑚, TF motif occurrences are overlapped with 𝑛!,!,! foreground and 𝑛!,!,! 
background feDMRs, while 𝑛!,! = 𝑛!,!,! + 𝑛!,!,! is the total number of overlapping 
feDMRs. The probability of observing 𝑛!,!,! or more overlapping foreground feDMRs 
(p-value) is defined as: 
P X ≥ 𝑛!,!,!|𝑁!,! ,𝑛!,!,!,𝑁!,! ,𝑛!,!,! =  !!,!! !!,!!!,!!!!!!!,!
!!,!
!!!!,!,!  
 For each tissue type, we performed this test for all motifs (n=532). Then, the p-
values of each tissue were adjusted using Benjamini-Hochberg method and the motifs 
were called as significant if they passed 1% FDR cutoff. Lastly, we excluded any TF-
binding motifs whose TF expression level was less than 10 TPM. 
 
Enrichment of GWAS SNPs in feDMRs 
            A set of genome-wide association study (GWAS) SNPs were utilized from the 
GWAS Catalog77 (gwas_catalog_v1.0-associations_e86_r2016-11-28.tsv). We filtered 
out SNPs with missing coordinates or missing p-value information as well as those with 
p-values greater than 5x10-8, resulting in a final set of 13,470 GWAS SNPs. Next, we 
used liftOver from the UCSC genome browser65 to convert the SNP coordinates from 
hg38 human reference genome to hg19, resulting in the exclusion of only 4 SNPs. We 
further selected SNPs that could be lifted over to mm10 mouse reference genome, 
resulting in a final set of 7,052 GWAS SNPs that are conserved between human and 
mouse; these were included in the following analysis.  
 Next, to obtain orthologous regions from the human genome of the mouse CG-
DMRs, we used liftOver to map mouse CG-DMRs (mm10) to hg19, requiring that at 
least 50% of the bases in CG-DMR could be assigned to hg19 (using option -
minMatch=0.5). In total, 1,034,801 out of 1880810 (55%) of mouse DMR regions could 
be aligned to the human genome. 
Finally, we overlapped the human orthologous regions of the mouse feDMRs for 
each tissue/organ with the GWAS SNPs and tested for enrichment using a one-tailed 
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hypergeometric test. Specifically, for each tissue/organ, we separately overlapped GWAS 
SNPs with the human orthologous regions for distal feDMRs in that tissue/organ 
(foreground) and the human orthologous regions for the remaining CG-DMRs 
(background), Using the statistical approach (described below) for SNPs associated with 
each trait, we tested for their enrichment in the human orthologous regions for distal 
feDMRs compared to background. We then used Benjamini-Hochberg approach to adjust 
the p-values for multiple testing. P-value cutoff given 5% false discovery rate (FDR) was 
used to call significant enrichment. This procedure was conducted separately for the 
distal feDMRs of each tissue/organ.  
In brief, we used a one-tailed hypergeometric test to test for enrichment. We 
defined q! as the number of GWAS SNPs that are associated with trait c and are 
overlapped with distal feDMRs. Therefore, the total number of SNPs overlapped with 
foreground is Q = q!! . Similarly, we defined B = b!!  as the number of SNPs that are 
overlapped with background where b! SNPs were associated with trait 𝑐. For each trait c, 
the null hypothesis was that q! follows a hypergeometric distribution, with population 
size as 𝑁 = 𝑄 + 𝐵, number of successes (here the number of SNPs related to 𝑐 that are 
overlapped with either foreground or background) as n! = 𝑞! + 𝑏!, and sampling number 
as 𝑄. Let X be a random variable representing the observed number of SNPs that are 
related to trait 𝑐 and overlapped with foreground. Thus, the probability of observing X is 
equal to or greater than 𝑞! (i.e. p-value) is calculated as: 
P X ≥ q!|N, 𝑞! + 𝑏! ,Q, c =  !!! !!!!!!!!!
!
!!!!  
 
Categorizing CG-DMRs 
To better understand the potential functions of CG-DMRs, we grouped them into 
various categories based on their genomic location and chromatin signatures. First, we 
overlapped CG-DMRs with promoters, CGIs and CGI shores and defined the CG-DMRs 
overlapping these locations as proximal CG-DMRs. Out of the 153,019 proximal CG-
DMRs, 46,692, 90,831, 1,710 and 13,786 overlapped with CGI promoters, non-CGI 
promoters, CGIs and CGI shores, respectively. We avoided assigning proximal CG-
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DMRs into multiple categories by prioritizing the four genomic features as CGI promoter, 
non-CGI promoter, CGI and CGI shores (ordered in decreasing priority). Each CG-
DMRs was assigned to the category with the highest priority. 
 We further classified the remaining 1,655,791 distal CG-DMRs: 1) 415,227 of 
them were predicted as distal feDMRs (CG-DMRs that show enhancer-like chromatin 
signatures34,35) as described in the previous method section. (2) Next, we defined flanking 
distal feDMRs or fd-feDMRs as the CG-that were within 1kb to distal feDMRs but were 
not predicted as enhancers (feDMRs). In total we found 221,960 such CG-DMRs.  
 
(3) Then, among the remaining, unclassified CG-DMRs, 194,610 CG-DMRs were 
identified tissue-specific CG-DMRs in at least one of the tissues because they displayed 
strong tissue-specific hypomethylation patterns (mCG difference ≥ 0.3). By checking the 
enrichment of histone marks in their hypomethylated tissues, we found they were 
enriched for H3K4me1 but not other histone marks, and such chromatin signatures 
resembled that of primed enhancers42. Therefore, we defined these CG-DMRs as primed 
distal feDMRs or pd-feDMRs. 
 
(4) Lastly, we defined the remaining CG-DMRs as unexplained CG-DMRs (unxDMRs) 
because their functional roles could not be assigned yet. We found unxDMRs have strong 
overlap with transposable elements and we further divided them into two classes: te-
unxDMRs and nte-unxDMRs. te-unxDMRs are unxDMRs that are overlapped with 
transposable elements, while the remaining were nte-unxDMRs. 
 
Evolutionary Conservation of CG-DMRs 
The evolutionary conservation of CG-DMRs were measured using phyloP score78 
from the UCSC genome browser65 
(http://hgdownload.cse.ucsc.edu/goldenpath/mm10/phyloP60way/mm10.60way.phyloP6
0way.bw). Next, Deeptools269 was used to generate the profile of evolutionary 
conservation of the CG-DMR centers and +/- 5kb flanking regions using options 
“reference-point --referencePoint=center -a 5000 -b 5000”. 
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Finding TF-binding Motifs Enriched in Flanking Distal feDMRs 
To identify the TF-binding motifs enriched in fd-feDMRs relative to feDMRs, we 
performed motif analysis using the former as foreground and the latter as background. 
Specifically, for each tissue, the tissue-specific feDMRs were used as background, while 
fd-feDMRs that were within 1kb of these tissue-specific feDMRs were used as 
foreground. To avoid potential bias residing in different size distribution, both foreground 
and background regions were extended from both sides (5’ and 3’) such that both had 
mean size of 400bp. Next a hypergeometric test was performed to find TF-binding motifs 
that were significantly enriched in foreground. This test was the same as that used for the 
identification of TF-binding motifs in feDMRs.  
 
TF-binding Motif Enrichment Analysis for Primed Distal feDMRs 
We also performed motif analysis to identify TF-binding motifs enriched in pd-
feDMRs. The procedure was similar to the motif enrichment analysis on feDMRs. For 
each tissue, the pd-feDMRs hypomethylated in that tissue were considered as foreground 
while the remaining pd-feDMRs were considered as background. Then, a hypergeometric 
test was performed to identify significant motif enrichment.  
 Next, for each tissue type, we compared the TF-binding motifs enriched in pd-
feDMRs and the tissue-specific feDMRs. The hypergeometric test was used to test the 
significance of overlap – the chance of obtaining the observed overlap if the two lists 
were based on random sampling (without replacement) from the TF-binding motifs with 
TF expression level greater than 10 TPM. 
 
Permutation Test of the Overlap between unxDMR and TEs 
To estimate the significance of overlap between unxDMRs and TEs, we shuffled 
the location of unxDMRs using “shuffleBed” tool from bedtools74 with default setting 
and recalculated the overlaps. After repeating this step for 1,000 times, we obtained an 
empirical estimate of the overlap if unxDMRs were randomly distributed in the genome. 
Let the observed number of TE overlapping unxDMRs be 𝑥!"# and the number of TE 
overlapping shuffled unxDMRs in permutation 𝑖 be 𝑥!!"#$%&. We then calculated p-values 
as 
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𝑝 = 𝐼(𝑥!"# ≤ 𝑥!!"#$%&!"""!!! ) + 11000+ 1  
where 𝐼 𝑥 = {!!    !!!"#$  !!!"#$%.  
 
Quantification of the mCG Dynamics in Tissue-Specific CG-DMRs 
To quantify mCG dynamics, we defined and counted loss-of-mCG and gain-of-
mCG events. A loss-of-mCG (Gain-of-mCG) event is a decrease (increase) of mCG level 
by at least 0.1 in one CG-DMR in one stage interval. For example, if the mCG level of 
one CG-DMR at E11.5 and E12.5 is 0.8 and 0.7 in heart respectively, it is considered a 
loss-of-mCG event occurred at the stage interval E11.5-E12.5. Stage interval is defined 
as the transition between two sampled adjacent stages(e.g. E15.5 and E16.5). 
 
Clustering Forebrain-specific CG-DMRs based on mCG and H3K27ac Dynamics 
We used k-means clustering to identify subgroups of forebrain-specific CG-DMR 
based on mCG and H3K27ac dynamics. First, for each forebrain-specific CG-DMR, we 
calculated the mCG level and H3K27ac enrichment in forebrain samples from E10.5 to 
adult stages. Here, we used methylome data for postnatal 1, 2 and 6 week frontal cortex 
from Lister et al10 to approximate the DNA methylation landscape of adult forebrain. We 
also incorporated H3K27ac data for postnatal 1, 3 and 7 week forebrain samples. Next, to 
make the range H3K27ac enrichment values comparable to that of mCH levels, for each 
forebrain-specific CG-DMR, the negative H3K27ac enrichment values were thresholded 
as zero and then each value was divided by the maximum. If the maximum was zero for 
some forebrain-specific CG-DMRs, we set all values to be zero. k-means clustering was 
of subgroups was carried out but no new patterns were observed. Lastly, we used 
GREAT79 employing the “Single nearest gene” association strategy to identify the 
enriched gene ontology terms of genes near CG-DMRs for each subgroup. 
 
Association Between mCG level and H3K27ac Enrichment 
To investigate the association between mCG and H3K27ac, for each tissue and 
each developmental stage, we first divided the tissue-specific CG-DMRs into three 
categories based on mCG methylation levels: H (highly CG methylated; mCG level > 
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0.6), M (moderately CG methylated; 0.2 < mCG level ≤ 0.6) and L (lowly CG methylated; 
mCG level ≤ 0.2). Then, we examined the distribution of H3K27ac enrichment in 
different groups of CG-DMRs by counting the number of CG-DMRs for each of four 
levels of H3K27ac: [0,2 ], (2, 4], (4, 6] and (6, ∞). 
 
Weighted Correlation Network Analysis (WGCNA) 
We used weighted correlation network analysis (WGCNA)80, an unsupervised 
method, to detect sets of genes with similar expression profiles across samples (R 
package, “WGCNA” version 1.51). Briefly, TPM values were First log2 transformed 
(with pseudo count 1e-5). Then, the TPM value of every gene across all samples was 
compared against the expression profile of all other genes and a correlation matrix was 
obtained. To obtain connection strengths between any two genes, we transformed this 
matrix to an adjacency matrix using a power adjacency function. To choose the parameter 
(soft threshold) of the power adjacency function, we used the scale-free topology (SFT) 
criterion, where the constructed network is required to at least approximate scale-free 
topology. The SFT criterion recommends use of the first threshold parameter value where 
model-fit saturation is reached as long as it is above 0.8. In this study, the threshold was 
reached for a power of 5.  
Next, the adjacency matrix is further transformed to a topological overlap matrix 
(TOM) that finds “neighborhoods” of every gene iteratively, based on the connection 
strengths. The TOM was calculated based on the adjacency matrix derived using the 
signed hybrid network type, biweight mid correlation and signed TOMtype parameters of 
the TOMsimilarityFromExpr module in WGCNA. Hierarchical clustering of the TOM 
was done using the flashClust module using the average method. Next, we used the 
cutreeDynamic module with the hybrid method, deepSplit = 3 and minClusterSize = 30 
parameters to identify modules that have at least 30 genes. A summarized module-
specific expression profile was created using the expression of genes within the given 
module, represented by the eigengene. The eigengene is defined as the first principal 
component of the log2 transformed TPM values of all genes in a module. In other words, 
this is a virtual gene that represents the expression profile of all genes in a given module. 
Next, very similar modules were merged after a hierarchical clustering of the eigengenes 
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of all modules applying a distance threshold of 0.15. Finally, the eigengenes were 
recalculated for all modules after merging. 
 
Gene Ontology Analysis of Genes in Co-expression Modules (CEM) 
To better understand the biological processes of genes in each CEM, we used 
Enrichr81,82 (http://amp.pharm.mssm.edu/Enrichr/) to identify the enriched gene ontology 
terms in the “GO_Biological_Process_2015” category.  
 
Correlating Eigengene Expression with mCG and Enhancer Scores of feDMRs 
We investigated the association between gene expression and epigenomic 
signatures of regulatory elements in CEMs. First, for each CEM, we used the eigengene 
expression to summarize the transcription patterns of all genes in the module. Then, we 
calculated the normalized average enhancer score and normalized average mCG level of 
all feDMRs that were linked to the genes in the CEM. Specifically, to reduce the 
potential batch effect, for each tissue and each stage, we normalized the enhancer score of 
each feDMR by the mean enhancer score of all feDMRs. mCG levels of feDMRs were 
normalized in similar way except that the data of all DMRs was used to calculate the 
mean mCG level for each tissue and each stage. Next, for each CEM, the TPM of its 
eigengene, the normalized average enhancer score and mCG level of linked feDMRs 
were converted to z-scores across all fetal stages for each tissue type (for analysis for 
tissue-specific expression) or across tissue types for each development stage (for analysis 
for temporal expression). Lastly, for each CEM, we calculated the Pearson correlation 
coefficient (R 3.3.1) between the z-score of eigengene expression and the z-score of 
normalized enhancer score (or mCG level) for each module. The correlation coefficients 
were calculated for two different settings: 1) for each tissue type, the correlation was 
computed using z-score of normalized eigengene expression values and enhancer scores 
(or mCG levels) across different development stages or 2) for each developmental stage, 
the correlation was computed across different tissue types. The coefficients from the 
former analysis indicate how well temporal gene expression is correlated with enhancer 
score or mCG level of regulatory elements, while the latter measures the association with 
tissue-specific gene expression. 
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We then test whether the correlation that we observed was significant by 
comparing it with the correlation based on shuffle data. In the analysis for tissue-specific 
expression in a given tissue type, we mapped the eigengene expression of one CEM to 
the enhancer score (or mCG level) of feDMRs linked to genes in a randomly chosen 
CEM. For example, in the shuffle setting, when given tissue type was heart, we 
calculated the correlation between the eigengene expression of CEM14 and the enhancer 
score of the feDMRs linked to genes in CEM6. In the analysis for temporal expression, 
given a specific developmental stage, we performed similar permutation. Next, we 
calculated the Pearson correlation coefficients for this permutation setting. Lastly, using a 
two-tailed Mann-Whitney test, we compared the median of observed correlation 
coefficients and the median of those based on shuffled data.  
 
Identification of Large Hypo CG-DMRs 
Large hypo CG-DMRs were called using the same procedure as previously 
described46. For each tissue type, tissue-specific CG-DMRs were merged if they are 
within 1kb of each other. Then, we filtered out merged CG-DMRs less than 2kb in length.  
 We overlapped genes with large hypo CG-DMRs and then filtered out any genes 
with names starting with “Rik” or “Gm[0-9]”, where [0-9] represents a single digit, 
because the ontology of these genes were ill-defined. 
 
Super-enhancer Calling 
Super-enhancers were identified using ROSE83,84 pipeline. First, H3K27ac peaks 
were called using macs270 callpeak module with options “--extsize 300 -q 0.05 --nomodel 
-g mm”. Control data was used in the peak-calling step. Next, ROSE was run with 
options “-s 12500 -t 2500”, and H3K27ac peaks, mapped H3K27ac ChIP-seq reads and 
mapped control reads as input. The super-enhancers calls were generated for each tissue 
sample. Then, we obtained the super-enhancers of one tissue type by merging the super-
enhancers called at each stage of fetal development (E10.5 to P0). Last, we generated a 
list of merged super-enhancers by merging super-enhancer calls of all tissue types except 
liver. 
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DNA Methylation Valley (DMV) Identification 
We identified DMVs as previously described55. First, genome was dividing into 
1kb non-overlapping bins. Then, for each tissue sample (replicate), consecutive bins with 
mCG level less than 0.15 were merged into blocks; bins with no data (no CG sites or no 
reads) were skipped. Next, any blocks merged from no less than 5 with-data bins were 
called as DMVs. For each tissue sample, we filtered for DMVs reproducible in two 
replicates by first selecting the DMVs identified in one replicate that are overlapped any 
DMVs called in the other replicate, and then merging overlapping DMVs. Using this 
strategy, we obtained DMV calls for each tissue from each developmental stage. Lastly, 
we got a list of merged DMVs for all tissue samples by merging all DMVs identified in 
any tissues from any developmental stages. 
 We overlapped genes with DMVs and then filtered out any genes with names 
starting with “Rik” or “Gm[0-9]”, where [0-9] represents a single digit, because the 
ontology of these genes were ill-defined. 
 
Partially Methylated Domain (PMD) Identification 
PMDs were identified as previously described9 using random forest classifier. To 
train the classifier, we first visually selected regions on chromosome 19 as strong 
candidates for PMDs or non-PMDs in E14.5 liver sample. Specifically, we manually 
annotated 5 PMDs with which showed obvious lower mCG level compared to adjacent 
genomic regions (chr19:46110000-46240000, chr19:45820000-45960000, 
chr19:47140000-47340000 and chr19:48060000-52910000) and 7 Non-PMD regions 
(chr19:4713800-4928700, chr19:7420700-7541100, chr19:8738100-8967000, 
chr19:18633300-18713800, chr19:53315500-53390000, chr19:55256600-55633900 and 
chr19:59281600-59329200).  
Next, these regions were divided into 10kb non-overlapping bins and we 
calculated the percentiles of the methylation levels at the CG sites within each bin. CG 
sites that were within CGIs, DMVs55 or any of four Hox loci (see below) were excluded 
as these regions are typically hypomethylated which may result in incorrect PMD calling. 
Additionally, sites with less than 5 reads covered were also excluded. We trained the 
random forest classifier using data from E14.5 liver (combining the two replicates) and 
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we then predicted whether a 10kb bin was a PMD or non-PMD in all liver samples 
(considering replicates separately). We chose a large bin size (10 kb) to reduce the effect 
of smaller scale methylation variation (such as DMRs) as PMDs were first discovered as 
large (mean length = 153kb, PMID: 19829295) regions with intermediate methylation 
level (< 70%, PMID: 19829295). Furthermore, the features (the distribution of 
methylation level of CG sites, which measured the fraction of CG sites that showed 
methylation level at various methylation level ranges) used in the classifier required 
enough CG sites within each bin to robustly estimate the distribution, which necessitated 
a relatively large bin. Also, we excluded any 10kb bins containing less than 10 CG sites 
for the same reason. These percentiles were used as features for the random forest. The 
random forest implement was from scikit-learn (version 0.17.1)85 python module and the 
following arguments were supplied to the Python function RandomForestClassifier from 
scikit-learn: n_estimators = 10000, max_features=None, oob_score=True, 
compute_importances=True.  
Lastly, we merged consecutive 10kb bins that were predicted as PMD into blocks 
and filtered out blocks smaller than 100kb. We further excluded blocks that overlapped 
with gaps in mm10 genome (downloaded from UCSC genome browser, Sep 21, 2013). 
To obtain a set of PMDs that were reproducible in both replicates, we only considered 
genomic regions that were larger than 100kb and were covered by PMD calls in both 
replicates. These regions were the final set of PMDs used for later analyses. Because 
there was only one replicated for adult liver, we called the PMDs at this stage using the 
single replicate.  
PMDs were originally called using the above procedure without excluding CG 
sites in Hox gene clusters. However, because these Hox loci are more likely to be 
considered as large DMVs55, we removed any PMD that overlapped with the four Hox 
clusters (chr11:96257739-96358516, chr15:102896908-103038064, chr2:74648392-
74748841 and chr6:52146273-52277140).  
 
Overlap Between PMDs and LADs 
To examine the relationship between PMDs and lamina associated domains 
(LADs) in normal mouse liver cells (AML12 hepatocyte) we utilized LAD data in the 
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Table S2 from Fu et al86. The mm9 coordinates of LADs were converted to mm10 using 
liftOver with default settings. We then used permutation testing to examine the 
significance of the overlap between PMDs and LADs. Similar to the procedure for 
checking the overlap between TEs and unxDMRs, we permutated (1000 times) the 
genomic locations of PMDs and recorded the number of overlapping bases (𝑥!!!!"for 
permutation 𝑖) between shuffled PMDs and LADs. Then, we compared 𝑥!!!!" with the 
observed numbers of overlapping bases (𝑥!"#) between PMDs and LADs and computed 
p-values as: 𝑝 = 𝐼(𝑥!"# ≤ 𝑥!!!!"!"""!!! ) + 11000+ 1  
where 𝐼 𝑥 = {!!    !!!"#$  !!!"#$%.  
 
Replication Timing Data 
Replication timing data (build mm10) of three mouse cell types was utilized from 
ReplicationDomain87. The cell types used for these analyses were mESC (id: 
1967902&4177902_TT2ESMockCGHRT), neural progenitor cells (id: 
4180202&4181802_TT2NSMockCGHRT) and mouse embryonic fibroblasts (id: 
304067-1 Tc1A).  
 
Gene Expression in PMDs 
We obtained PMD overlapping protein-coding genes information using 
“intersectBed”. A similar approach was used to obtain the protein-coding genes 
overlapped with PMD flanking regions (upstream 100kb and downstream 100kb of 
PMDs); genes overlapping with PMDs were removed from this list. Lastly, we compared 
the expression of PMD-overlapping genes (n=5,748) and the genes (n=2,555) 
overlapping with flanking regions. 
 
 
Sequence Context Preference of mCH 
To interrogate the sequence preference of mCH, as previous described9, we first 
identified CH sites that showed a significantly higher methylation level than the low level 
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noise (which was around 0.005 in term of methylation level) caused by incomplete 
sodium bisulfite non-conversion. For each CH site, we counted the number of reads that 
supported methylation and the number of reads that did not. Next, we performed a 
binomial test with the success probability equal to the sodium bisulfite non-conversion 
rate. FDR (1%) was controlled using the Benjamini-Hochberg approach88. This analysis 
was independently performed for each three-nucleotide context (e.g., a pvalue cutoff was 
calculated for CAG cytosines). Lastly, we counted sequence motif occurrence of +/-5bp 
around the tri-nucleotide context of methylated mCH sites and visualized the sequence 
preferences using seqLogo89 
 
Calling mCH Domains 
We used an iterative process to call mCH domains, which are genomic regions 
that are enriched for mCH compared to flanking regions. First, we selected a set of 
samples that showed no evidence of mCH. Data from these samples were used in the 
following steps to filter out genomic regions that are prone to misalignment and showed 
suspicious mCH abundance. Analysis of the global mCH level and mCH motifs revealed 
that E10.5 and E11.5 tissues (excluding heart samples) have extremely low mCH and the 
significantly methylated non-CG sites showed little CA preference. Therefore, we 
assumed these sites contain no mCH domain and any mCH domain called in control 
samples by the algorithm were likely artifacts. By filtering out the domains called in the 
control samples, we were able to exclude the genomic regions that were prone to 
mapping error or avoid other potential drawbacks in the processing pipeline. 
 In order to identify genomic regions where sharp changes in mCH levels occurred, 
we applied a change point detection algorithm with the mCH levels of all 5kb non-
overlapping bins across the genome as input. We only included bins that contained at a 
minimum 500 CH sites and at least 50% of CH sites were covered by 10 or more reads. 
The identified regions defined the boundaries that separate mCH domains from genomic 
regions showing background level mCH. We implemented this step using the function 
cpt.mean in R package “changepoint”, with options “method="PELT", pen.value=0.05, 
penalty="Asymptotic" and minseglen=2”. . To match the range of chosen penalty, we 
scaled up mCH levels by a factor of 1,000.  
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 The iterative procedure was carried out as follows: 1) An empty list of excluded 
regions was created. 2) For each control sample, the change point detection algorithm 
was applied to the scaled mCH levels of 5kb non-overlapping bins. Bins overlapping with 
excluded regions were ignored. 3) The genome was segmented into chunks based on 
identified change points. 4) The mCH level of each chunk was calculated as the mean 
mCH level of the overlapping 5kb bins that were not overlapped with excluded regions. 5) 
mCH domains were identified as chunks whose mCH level was at least 50% greater than 
the mCH level of both upstream and downstream chunks. The pseudo mCH level of 
0.001 was used to avoid dividing zero. 6) mCH domains were added to the list of 
excluded regions. 7) Step 2 to 6 were repeated until the list of excluded regions stop 
expanding. 8) Steps 2-5 were then applied to all samples. 9) For each tissue/organ, only 
regions were retained that were identified as (part of) an mCH domain in both replicates 
and regions less than 15kb in length were filtered out; mCH domains must span at least 
three bins. The above criterion were used to define mCH domains for each tissue/organ. 
10) Individual mCH domains from each tissue and organ were merged to obtain a single 
combined list of 384 mCH domains. 
 
Clustering of mCH Domains  
We applied k-means clustering to group the 384 identified mCH domains into 5 
clusters based on the normalized mCH accumulation profile of each mCH domain and 
corresponding flanking regions (100kb upstream and 100kb downstream). Specifically, 
1) in each tissue sample, the mCH accumulation profile of one mCH domain was 
represented as a vector of length 50: the mCH level of 20 5kb bins upstream mCH 
domain, 10 bins that equally divided the mCH domain and 20 5kb bins downstream. 2) 
Then, we normalized all values by the average mCH level of bins of flanking regions (the 
20 5kb bins upstream and 20 5kb bins downstream of mCH domain). 3) We next 
computed the profile in samples of 6 tissue types (midbrain, hindbrain, heart, intestine, 
stomach and kidney) that showed the most evident mCH accumulation in fetal 
development. 4) Using the profile of these tissue samples, k-means (R v3.3.1) was used 
to clustered mCH domains with k = 5. We also tried higher cluster numbers (e.g. 6) but 
did not identify any new patterns. Even using the current k setting (k=5), the mCH 
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/166744doi: bioRxiv preprint first posted online Jul. 21, 2017; 
	 66 
domains in clusters 1 (C1) and 3 (C3) shared similar mCH accumulation pattern. 
 
Genes in mCH Domains  
We obtained the overlapping gene information for each of the mCH domains by 
overlapping gene bodies with mCH domains using “intersectBed” in bedtools74. Only 
protein coding genes were considered. We further filtered out any genes with names 
starting with “Rik” or “Gm[0-9]”, where [0-9] represents a single digit, because the 
ontology of these genes were ill-defined. For the overlapping genes of each mCH domain 
cluster, we used EnrichR81,82 to find the enriched gene ontology terms 
(“GO_Biological_Process_2015”).  
Next we asked whether the identified overlapping genes were enriched for TF 
encoding genes. For this purpose, a list of mouse TFs from AnimalTFDB90 (Feb 27, 2017) 
was utilized. We then performed a permutation test to estimate the significance of the 
findings. Specifically, 𝑥!"# is the number of TF encoding genes in all overlapping genes. 
We randomly selected (1000 times) the same number of genes and in the 𝑖th time, 𝑥!!"#$%& of the randomly selected genes encoding TFs. Lastly, the p-values was 
calculated as 𝑝 = 𝐼(𝑥!"# ≤ 𝑥!!"#$%&!"""!!! ) + 11000+ 1  
where 𝐼 𝑥 = {!!    !!!"#$  !!!"#$%.  
 
mCH Accumulation Indicates Gene Repression 
To evaluate the association between mCH abundance and gene expression, we 
traced the expression dynamics of genes inside mCH domains. For mCH domains in each 
cluster, we first calculated the TPM z-score for each of the overlapping genes. 
Specifically, for each tissue type and each overlapping gene, we normalized TPM values 
in the samples of that tissue type to z-scores. The z-scores showed the trajectory of 
dynamic expression, in which the aptitude information of expression was removed. If the 
gene was not expressed, we did not perform the normalization. Next, we calculated the z-
scores for all genes that had no overlapped with any mCH domain. Lastly, we subtracted 
the z-scores of overlapping genes by the z-scores of all genes outside mCH domains. The 
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resulting values indicated the level of expression of genes in mCH domains relative to 
genes not in mCH domains. 
 
feDMRs in mCH Domains 
To evaluate whether feDMRs were enriched in mCH domains, we calculated the 
percentage of bases within mCH domains that were also within tissue-specific feDMRs. 
Specifically, we first divided the genome into non-overlapping 100bp bins and then, for 
each tissue, we calculated the percentage of bases in each bin that overlapped with tissue-
specific feDMRs. Next, we plotted such percentages across mCH domains (each was 
equally divided into 10 non-overlapping bins) and flanking regions (10kb upstream and 
10kb downstream; each contained 10 1kb bins).  
For the feDMRs that overlapped with mCH domains, we then traced their mCG 
levels as they changed over developmental time. For each tissue type and each 
developmental stage, we calculated the percentage of tissue-specific feDMRs whose 
mCG level was in each range: [0-0.2), [0.2, 0.4), [0.4, 0.6), [0.6, 0.8) and [0.8, 1]. For 
each tissue and each developmental stage, these percentages were calculated for tissue-
specific feDMRs in mCH domains and also for all tissue-specific feDMRs. Lastly, the 
ratio of the former to the later was defined as the enrichment of feDMRs (with certain 
mCG level) in mCH domains, which was then transformed to log2 ratio. 	
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